Cingulate Q2 EPS Increased by Ascendiant Capital Markets

Cingulate Inc. (NASDAQ:CING) – Research analysts at Ascendiant Capital Markets lifted their Q2 2026 earnings per share estimates for shares of Cingulate in a report issued on Saturday, June 6th. Ascendiant Capital Markets analyst E. Woo now forecasts that the company will earn ($0.33) per share for the quarter, up from their previous estimate of ($0.38). Ascendiant Capital Markets currently has a “Buy” rating and a $52.00 target price on the stock. The consensus estimate for Cingulate’s current full-year earnings is ($2.34) per share. Ascendiant Capital Markets also issued estimates for Cingulate’s Q3 2026 earnings at ($0.33) EPS, Q4 2026 earnings at ($0.33) EPS, FY2026 earnings at ($1.81) EPS, Q1 2027 earnings at ($0.36) EPS, Q2 2027 earnings at ($0.36) EPS, Q3 2027 earnings at ($0.28) EPS, Q4 2027 earnings at ($0.28) EPS and FY2027 earnings at ($1.29) EPS.

CING has been the subject of a number of other research reports. Wall Street Zen lowered Cingulate from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 16th. HC Wainwright restated a “buy” rating and issued a $20.00 target price on shares of Cingulate in a research note on Tuesday, May 26th. Roth Mkm restated a “buy” rating and issued a $10.00 target price on shares of Cingulate in a research note on Tuesday, May 19th. Finally, Weiss Ratings upgraded Cingulate from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 22nd. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $27.33.

Cingulate Price Performance

Shares of CING stock opened at $4.89 on Thursday. The firm has a market capitalization of $65.87 million, a price-to-earnings ratio of -1.16 and a beta of -0.85. The business has a fifty day moving average of $5.08 and a 200 day moving average of $5.41. Cingulate has a 1 year low of $3.16 and a 1 year high of $11.89.

Cingulate (NASDAQ:CING) last issued its earnings results on Thursday, May 14th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.42).

Hedge Funds Weigh In On Cingulate

A number of institutional investors have recently modified their holdings of CING. XTX Topco Ltd purchased a new position in shares of Cingulate during the 2nd quarter valued at about $45,000. Bank of America Corp DE lifted its holdings in Cingulate by 283.1% in the second quarter. Bank of America Corp DE now owns 7,501 shares of the company’s stock valued at $31,000 after acquiring an additional 5,543 shares during the period. Quantum Private Wealth LLC lifted its holdings in Cingulate by 140.0% in the third quarter. Quantum Private Wealth LLC now owns 24,000 shares of the company’s stock valued at $94,000 after acquiring an additional 14,000 shares during the period. Soltis Investment Advisors LLC purchased a new stake in Cingulate in the 4th quarter worth approximately $43,000. Finally, Geode Capital Management LLC grew its stake in shares of Cingulate by 43.9% during the 4th quarter. Geode Capital Management LLC now owns 61,035 shares of the company’s stock worth $265,000 after purchasing an additional 18,629 shares during the period. Hedge funds and other institutional investors own 41.31% of the company’s stock.

About Cingulate

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.